{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T04:12:28Z","timestamp":1793592748009,"version":"4.5.0"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Public Health Ontario"},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The BioPlex 2200 (Bio-Rad Laboratories, Hercules, CA) is a rapid, automated platform, which can screen large numbers of specimens for antibodies to measles, mumps, rubella, and varicella. Although approved for producing qualitative results, in this study we validated the test (off-label) to allow reporting of quantitative results. To do this, we used the third anti-measles World Health Organization standard to generate a calibration curve that allowed relative fluorescence intensity to be translated into quantitative antibody titer (antibody units [AU]\/ml). The results from the BioPlex 2200 and the reference plaque reduction neutralization test (PRNT) exhibited a reasonable correlation following an exponential function, but correlation was poor in low-titer samples. Using a receiver operating characteristics analysis, an equivocal zone for the BioPlex 2200 was established between \u22650.13 and &lt;1.10 AU\/ml to achieve 100% specificity (95% confidence interval [CI] = 83.2 to 100%) and 100% sensitivity (95% CI = 93.5 to 100%) versus PRNT. By determining an equivocal range requiring confirmation by PRNT, we can avoid underestimating the levels of immunity through false-negative results and optimize methods for seroepidemiological studies.<\/jats:p>","DOI":"10.1128\/cvi.00269-16","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T04:00:33Z","timestamp":1479355233000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Calibration and Evaluation of Quantitative Antibody Titers for Measles Virus by Using the BioPlex 2200"],"prefix":"10.1128","volume":"24","author":[{"given":"Todd F.","family":"Hatchette","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada"},{"name":"Canadian Center for Vaccinology, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Scholz","sequence":"additional","affiliation":[{"name":"Bio-Rad Laboratories, Benicia, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Bolotin","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha S.","family":"Crowcroft","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Laboratory Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"McLachlan","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Severini","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"ACS-3","article-title":"An Advisory Committee Statement (ACS) Measles and Rubella Elimination Working Group","volume":"39","author":"Public Health Agency of Canada","year":"2013","unstructured":"Public Health Agency of Canada. 2013. An Advisory Committee Statement (ACS) Measles and Rubella Elimination Working Group. Guidelines for the prevention and control of measles outbreaks in Canada. Can Communicable Dis Rep39:ACS-3.","journal-title":"Guidelines for the prevention and control of measles outbreaks in Canada"},{"key":"e_1_3_2_3_2","volume-title":"Measles: global update","author":"Public Health Agency of Canada","year":"2015","unstructured":"Public Health Agency of Canada. 2015. Measles: global update. Public Health Agency of Canada, Ottawa, Ontario, Canada. http:\/\/www.phac-aspc.gc.ca\/tmp-pmv\/notices-avis\/notices-avis-eng.php?id=98."},{"key":"e_1_3_2_4_2","volume-title":"Measles cases and outbreaks","author":"Centers for Disease Control and Prevention","year":"2016","unstructured":"Centers for Disease Control and Prevention. 2016. Measles cases and outbreaks. Centers for Disease Control and Prevention, Atlanta, GA. http:\/\/www.cdc.gov\/measles\/cases-outbreaks.html."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.110506"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/148.4.639"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/162.5.1036"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199503000-00007"},{"key":"e_1_3_2_9_2","volume-title":"Document I\/LA6-A","author":"Clinical and Laboratory Standards Institute","year":"1997","unstructured":"Clinical and Laboratory Standards Institute. 1997. Detection and quantitation of rubella IgG antibody: evaluation and performance criteria for multiple component test products, specimen handling, and use of test products in the clinical laboratory; approved guideline. Document I\/LA6-A. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000109287.97518.67"},{"key":"e_1_3_2_11_2","first-page":"58","article-title":"Mitteilung der St\u00e4ndigen Impfcommission (STIKO) am RKI","volume":"8","author":"Robert Koch Institute","year":"2001","unstructured":"Robert Koch Institute. 2001. Mitteilung der St\u00e4ndigen Impfcommission (STIKO) am RKI. Fragen Antworten Verscheiden Impfungen. Epidemiol Bull8:58.","journal-title":"Fragen Antworten Verscheiden Impfungen"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2008.12.007"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-0934(81)90062-8"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.9.2.259-265.1979"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.4.811-815.1995"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.08.074"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268800058209"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530410024018"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.epidem.2012.05.001"},{"key":"e_1_3_2_20_2","article-title":"Analysis of the multiplex Bio-Rad BioPlex\u2122 2200 MMRV IgG kit","author":"Nicole M","year":"2009","unstructured":"Nicole M Ureda and AlanWu. 2009. Analysis of the multiplex Bio-Rad BioPlex\u2122 2200 MMRV IgG kit. Abstr Annu Clin Virol Symp Pan American Soc Clin Virol, abstr S-51.","journal-title":"Abstr Annu Clin Virol Symp Pan American Soc Clin Virol, abstr S-51"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05207-11"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.10.046"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199003013220903"},{"key":"e_1_3_2_24_2","volume-title":"Expert Committee On Biological Standardization: report on a collaborative study to investigate the relationship between the 1st IRP and the 2nd and 3rd international standards for anti-measles serum\/plasma, in both ELISA and PRNT","author":"Bentley M","year":"2007","unstructured":"Bentley M ChristianP HeathA, National Institute for Biological Standards and Control (NIBSC). 2007. Expert Committee On Biological Standardization: report on a collaborative study to investigate the relationship between the 1st IRP and the 2nd and 3rd international standards for anti-measles serum\/plasma, in both ELISA and PRNT. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/biologicals\/BS07%202076anti-measles.pdf."},{"key":"e_1_3_2_25_2","unstructured":"World Health Organization. 2009. The immunological basis for immunization series; module 7: measles update. World Health Organization Geneva Switzerland. http:\/\/apps.who.int\/iris\/bitstream\/10665\/44038\/1\/9789241597555_eng.pdf."},{"key":"e_1_3_2_26_2","volume-title":"Report of a collaborative study to assess the suitability of a replacement for theWHO\/BS\/06.2031","author":"World Health Organization","year":"2006","unstructured":"World Health Organization. 2006. Report of a collaborative study to assess the suitability of a replacement for the2nd international standard for anti-measles serum. WHO\/BS\/06.2031. World Health Organization, Geneva, Switzerland. https:\/\/extranet.who.int\/iris\/restricted\/handle\/10665\/70612.","edition":"2"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2006.12.017"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-2998(78)80014-2"},{"key":"e_1_3_2_29_2","first-page":"555","article-title":"Selection and interpretation of diagnostic tests and procedures","volume":"94","author":"Griner PF","year":"1981","unstructured":"Griner PF MayewskiRJ MushlinAI GreenlandP. 1981. Selection and interpretation of diagnostic tests and procedures. Ann Intern Med94:555\u2013600.","journal-title":"Ann Intern Med"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.06.095"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2005.08.001"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-007-0037-2"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/368040"},{"key":"e_1_3_2_34_2","volume-title":"Canadian Health Measures Survey","author":"Health Canada","year":"2014","unstructured":"Health Canada. 2014. Canadian Health Measures Survey. Health Canada, Ottawa, Ontario, Canada. http:\/\/www23.statcan.gc.ca\/imdb\/p2SV.pl?Function=getSurvey&Id=136652."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00269-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00269-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T15:43:03Z","timestamp":1627573383000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00269-16"}},"subtitle":[],"editor":[{"given":"Marcela F.","family":"Pasetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1128\/CVI.00269-16"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00269-16","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"2016-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-10-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}